Last reviewed · How we verify
Angle-closure glaucoma — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Neptazane | METHAZOLAMIDE | Pfizer | methazolamide | Carbonic anhydrase 3 | 1959-01-01 | |
| Diamox | ACETAZOLAMIDE | Teva | Carbonic Anhydrase Inhibitor [EPC] | Carbonic anhydrase | 1953-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Angle-closure glaucoma
- Pfizer · 1 drug in Angle-closure glaucoma
- Teva · 1 drug in Angle-closure glaucoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Angle-closure glaucoma:
- Angle-closure glaucoma treatment updates — RSS
- Angle-closure glaucoma treatment updates — Atom
- Angle-closure glaucoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Angle-closure glaucoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/angle-closure-glaucoma. Accessed 2026-06-10.
Related
- Angle-closure glaucoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing